<DOC>
	<DOCNO>NCT00482846</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , melphalan , work different way stop growth tumor cell , either kill cell stop dividing . Keratinocyte growth factor , palifermin , may help prevent symptom mucositis , mouth sore , patient receive melphalan peripheral stem cell transplant multiple myeloma . PURPOSE : This phase I trial study side effect best dose melphalan give together palifermin treat patient undergo autologous peripheral stem cell transplant stage II stage III multiple myeloma .</brief_summary>
	<brief_title>Melphalan Palifermin Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant Stage II III Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose high-dose melphalan administer palifermin patient undergo autologous peripheral blood stem cell transplantation stage II III multiple myeloma . Secondary - Assess overall response ( complete partial response stable disease ) patient 28 100 day post-transplantation . - Assess efficacy palifermin cytoprotective agent reduce incidence duration mucositis patient treat regimen . - Assess patient-reported outcome impact palifermin quality life patient . - Assess qualitative quantitative toxicity regimen patient . OUTLINE : This dose-escalation study melphalan . Patients stratify accord creatinine clearance ( normal v &lt; 60 mL/min ) . Patients receive high-dose melphalan IV day -2 palifermin IV day -5 -3 1-3 . Patients undergo autologous peripheral blood stem cell transplantation day 0 . In stratum , cohorts 3-6 patient receive escalate dos melphalan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients complete questionnaire overall health , mouth throat soreness ( MTS ) , activity limitation due MTS daily day -5 28 . After completion study treatment , patient follow day 28 100 periodically thereafter .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Stage II III disease Must undergone successful stem cell mobilization ( ≥ 2.0 x 10^6 CD34+ cells/kg ) No oral lesion etiology No unhealed mucositis induction treatment PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Amylase lipase normal Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN Creatinine normal ( stratum 1 ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No HIV positivity No history allergic reaction attribute melphalan No uncontrolled illness , include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia No psychiatric illness social situation would preclude study compliance No hepatitis B C positivity No prior concurrent pancreatitis No known sensitivity study drug , include E. coliderived product PRIOR CONCURRENT THERAPY : Prior bone marrow stem cell transplantation allow No prior palifermin More 30 day since prior investigational agent No concurrent dialysis No concurrent amifostine No concurrent prophylactic oral cryotherapy melphalan administration No concurrent mouthwash solution contain following : Chlorhexidine Hydrogen peroxide Diphenhydramine hydrochloride No concurrent recombinant interleukin11 sargramostim ( GMCSF ) No concurrent sucralfate suspension form Sucralfate tablet allow No concurrent povidoneiodine rinse No concurrent glutamine prophylactic agent mucositis No concurrent investigational agent No concurrent antithymocyte globulin suppression alemtuzumab No concurrent rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>mucositis</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>